Mineralys Therapeutics (MLYS) Expected to Release Earnings on Wednesday

Mineralys Therapeutics (NASDAQ:MLYS) is anticipated to post its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.5548) per share for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Mineralys Therapeutics (NASDAQ:MLYS) last announced its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30). On average, analysts expect Mineralys Therapeutics to post ($4.45) EPS for the current fiscal year and ($1.92) EPS for the next fiscal year.

Mineralys Therapeutics Stock Performance

NASDAQ:MLYS opened at $18.18 on Monday. The company has a market capitalization of $1.61 billion, a PE ratio of -4.29 and a beta of 0.69. Mineralys Therapeutics has a 52-week low of $18.11 and a 52-week high of $47.65. The stock’s 50 day moving average price is $24.78 and its 200 day moving average price is $27.03. The company has a quick ratio of 34.46, a current ratio of 34.46 and a debt-to-equity ratio of 0.18.

Insider Buying and Selling

In other news, CEO Jon Congleton sold 75,000 shares of the firm’s stock in a transaction on Wednesday, September 30th. The shares were sold at an average price of $25.46, for a total value of $1,909,500.00. Following the completion of the sale, the chief executive officer owned 528,621 shares in the company, valued at approximately $13,458,690.66. This trade represents a 12.43% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $28.58, for a total transaction of $85,740.00. Following the completion of the sale, the director directly owned 6,200 shares in the company, valued at approximately $177,196. The trade was a 32.61% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 199,365 shares of company stock worth $5,461,854 in the last ninety days. Insiders own 18.94% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Thursday, October 15th. HC Wainwright reiterated a “buy” rating and issued a $56.00 price target on shares of Mineralys Therapeutics in a research report on Monday, October 12th. Wall Street Zen cut shares of Mineralys Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 15th. Zacks Research raised shares of Mineralys Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, September 11th. Finally, UBS Group began coverage on shares of Mineralys Therapeutics in a research note on Sunday, October 11th. They issued a “neutral” rating and a $29.00 price objective on the stock. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $45.50.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney diseases associated with excess aldosterone activity. The company’s research centers on selectively targeting aldosterone production, a mechanism involved in blood-pressure regulation and organ damage.

Mineralys’ lead product candidate is lorundrostat, an oral, selective aldosterone synthase inhibitor being evaluated as a potential treatment for uncontrolled and resistant hypertension.